Sara Garcia-Ortega

Sara Garcia-Ortega

Auto-generated profile, based on publicly available information

Sara Garcia-Ortega

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d’Hebron Research Institute (VHIR), Vall d’Hebron Hospital Barcelona-UAB, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
PGPaula Granado-Martínez
Paula Granado-Martínez
SGSara Garcia-Ortega
Sara Garcia-Ortega
EGElena González-Sánchez
Elena González-Sánchez
KMKimberley McGrail
Kimberley McGrail
RSRafael Selgas
Rafael Selgas
JRJuan A. Recio
Juan A. Recio
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine.STK11(LKB1) appears to be inactivated in human cancer. However, somatic missense mutations also occur, and the role/s of these alterations to this disease remain unknown. Here, we investigated the contribution of four missense LKB1 somatic mutations in tumor biology. Three out of the four mutants lost their tumor suppressor capabilities and showed deficient kinase activity. The remaining mutant retained the enzymatic activity of wild type LKB1, but induced increased cell motility. Mechanistically, LKB1 mutants resulted in differential gene expression of genes encoding vesicle trafficking regulating molecules, adhesion molecules and cytokines. The differentially regulated genes correlated with protein networks identified through comparative secretome analysis. Notably, three mutant isoforms promoted tumor growth, and one induced inflammation-like features together with dysregulated levels of cytokines. These findings uncover oncogenic roles of LKB1 somatic mutations, and will aid in further understanding their contributions to cancer development and progression.

19 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KMKimberley McGrail
Kimberley McGrail
PGPaula Granado-Martínez
Paula Granado-Martínez
RERosaura Esteve-Puig
Rosaura Esteve-Puig
SGSara García-Ortega
Sara García-Ortega
YDYuxin Ding
Yuxin Ding
JRJuan A. Recio
Juan A. Recio
NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however,NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show thatNRASQ61-mutated melanomas specific metabolic settings mediate cell sensitivity to sorafenib upon metabolic stress. Mechanistically, these cells are dependent on glucose metabolism, in which glucose deprivation promotes a switch from CRAF to BRAF signaling. This scenario contributes to cell survival and sustains glucose metabolism through BRAF-mediated phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-2/3 (PFKFB2/PFKFB3). In turn, this favors the allosteric activation of phosphofructokinase-1 (PFK1), generating a feedback loop that couples glycolytic flux and the RAS signaling pathway. An in vivo treatment ofNRASQ61mutant melanomas, including patient-derived xenografts, with 2-deoxy-D-glucose (2-DG) and sorafenib effectively inhibits tumor growth. Thus, we provide evidence forNRAS-oncogene contributions to metabolic rewiring and a proof-of-principle for the treatment ofNRASQ61-mutated melanoma combining metabolic stress (glycolysis inhibitors) and previously approved drugs, such as sorafenib.